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Background: Although dysgeusia is a common adverse event in chemotherapy patients; it has not been evaluated
using objective methods, and its prevalence and frequency have not been quantified.
Methods: Salt-impregnated taste strips were used to objectively assess dysgeusia in patients receiving
chemotherapy at Akita University (n = 38) and those off chemotherapy (n = 9). Participant characteristics, and
ongoing and previous chemotherapies were evaluated, and their associations with dysgeusia analyzed.
Results: Dysgeusia developed in 38.8% (14/38) of chemotherapy patients, and was most prevalent in patients
receiving 5-fluorouracil (5-FU) or its oral analogs (48.1%, 13/27). Particularly, dysgeusia developed in 55.6% (10/18) of
patients receiving oral 5-FU analogs; however, prevalence in patients receiving and off chemotherapy was not
significantly different. Patients aged ≥70 years also tended to experience dysgeusia (75.0%, 6/8).
Conclusions: Association with dysgeusia may be higher for some chemotherapeutic drugs. Dysgeusia should be
routinely assessed in chemotherapy patients with objective methods such as paper strips; interventions for its
prevention may be required.
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Maintenance of quality of life (QOL) during chemothe-
rapy is important for patients with cancer. Although
alteration of taste (dysgeusia) is a nonlethal condition
that is often ignored, taste is critical to the pleasure of
eating, which is a major part of QOL [1,2]. Dysgeusia is
frequent in patients with cancer [3,4]. Care should be
taken to prevent dysgeusia, and when identified, appro-
priate therapy should be provided. Research has shown
that 60% of patients with advanced cancer experience
dysgeusia even without anticancer therapy [5].
Pathophysiological mechanisms of dysgeusia during
chemotherapy are explained by factors such as neuro-
logical damage in cranial nerves (VII, IX, and X) and
taste buds and mucosal damage [6]. Dysgeusia in the
cancer patient population is difficult to assess, and a* Correspondence: hiroyuki@med.akita-u.ac.jp
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reproduction in any medium, provided the orquantitative, validated methodology for evaluation has
not yet been established. Objective clinical research has
not been adequate and, often relies on anecdotal in-
formation. In this study, a salt-impregnated taste strip
was used to evaluate dysgeusia because of its objective-
ness, ease, and low cost. As reported in the literature, a
number of chemotherapeutic drugs, including cisplatin,
doxorubicin, 5-fluorouracil (5-FU), docetaxel, and pacli-
taxel, can induce dysgeusia [7]. These drugs, along with
the new oral 5-FU analogs, capecitabine and S1, are used
in the management of various types of malignancies
[8-13]. Because reports on the effects of these therapies
on taste have been anecdotal, we used an observational
objective approach to document and assess the actual
prevalence of dysgeusia in patient groups receiving
chemotherapy and those off chemotherapy (on- and
off-chemotherapy groups, respectively).. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Background of participants
Participants On-chemotherapy Off-chemotherapy
(n = 38) (n = 9)
Age 36–85 54–73
(median, 64) (median, 63)
Gender Male 25 Male 6
Female 13 Female 3
Malignancy Colorectal 14 Colorectal 4
Gastric 12 Gastric 2
Esophageal 5 STS 1
NET 3 Melanoma 1







NET neuroendocrine tumor, Pt platinum, STS soft tissue sarcoma, Tx taxane.
Table 2 Dysgeusia experienced in each patient
Age ≤59 60–69 70–79 ≥80 Total
Therapy
5-FU total 4/6 (66.7) 2/10 (20.0) 4/8 (50.0) 3/3 (100) 13/27 (48.1)
Oral analogs 2/3 (66.7) 2/7 (28.6) 4/6 (66.7) 2/2 (100) 10/18 (55.6)
5-FU 2/3 (66.7) 0/3 (0) 0/2 (0) 1/1 (100) 3/9 (33.3)
Pt 2/3 (66.7) 2/9 (22.2) 0/4 (0) - 16/38 (42.1)
Tx 1/3 (33.3) 0/1 (0) 1/1 (100) - 5/38 (13.2)
Others 0/3 (0) 1/6 (16.7) 0/1 (0) - 1/10 (10.0)
Off 0/2 (0) 1/3 (33.3) 1/3 (33.3) - 2/8 (25.0)
The number of patients who experienced dysgeusia during therapy is
indicated per total number undergoing chemotherapy. Numbers in
parentheses indicate the percentage. Type of chemotherapy is indicated in the
first column. Off off-chemotherapy.
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Patients of the Department of Clinical Oncology, Akita
University Hospital between February 2012 and December
2012 participated in this cohort study.
To objectively evaluate dysgeusia, we used the Salsave
kit® (AdvanTec, Tokyo, Japan), which is a validated salt
test using paper strips with 6 concentrations of sodium
chloride: 0.6%, 0.8%, 1.0%, 1.2%, 1.4%, and 1.6%. Partici-
pants initially tasted a paper strip with no salt crystals.
The test was then readministered step-by-step using
strips with lower to higher salt concentrations. Between
each step, each participant’s mouth was cleansed with
distilled water before the next tasting. The threshold of
the recognized concentration was recorded as a grade
of dysgeusia. If the participant could not recognize a
0.6% salt concentration, we deemed the participant’s
taste perception to have been altered. Dysgeusia was re-
corded with each therapy for each individual.
The Stat Mate III (ATMS, Tokyo, Japan) was used
to calculate relative risks. The level of statistical sig-
nificance was set to P < 0.05. This study was scientif-
ically and ethically approved by the Ethics Committee
of the School of Medicine of Akita University (#791).
Written informed consent was obtained from each




The participants included 31 male and 15 female pa-
tients, with an age range of 36–85 years and a me-
dian age of 64 years. All participants were diagnosed
with stage IV malignancies (Table 1). Nine patients
did not undergo chemotherapy while the study was
being conducted; corresponding chemotherapies ad-
ministered to the other 38 participants are listed in
Table 1. Patients receiving 5-FU-based therapy were
most frequently enrolled (27/38, 71.1%), followed by
those receiving platinum (Pt)-based therapy (16/38,
42.1%) and those receiving taxane (Tx)-based therapy
(5/38, 13.2%). Other comorbidities known to induce
dysgeusia, such as diabetes mellitus (DM) [14], brain
disease (BD) [15], and history of head and neck irra-
diation, were also evaluated [16]. Notably, of the
patients who had not received chemotherapy, 1 had
DM (11.1%, 1/9) and another had BD (11.1%, 1/9);
whereas of patients who received chemotherapy,
3 had DM (7.9%, 3/38) and 6 had BD (15.8%, 6/38).
During this study, 16 patients (42.1%, 16/38) re-
ceived ≥ 2 chemotherapies; no patient received head
and neck irradiation, but 1 underwent surgical re-
section for laryngeal sarcoma. However, no patient
suffered from oral mucositis or candidiasis in any of
the treatment groups.Prevalence of dysgeusia during chemotherapy
Of the 9 patients who did not receive chemotherapy
(aged 54, 57, 57, 61, 63, 67, 70, 71 and 73 years; median
age, 63 years), 7 successfully recognized the minimal salt
concentration (0.6%) and 2 did not (22.2%, 2/9; Table 2).
Even patients in the off-chemotherapy group expe-
rienced altered taste because of their past histories of
chemotherapies or other comorbidities. Of this group, 1
patient had received chemotherapy with S1 more than a
year previously. The other was chemotherapy-naïve but
had a history of BD. Among the other 7 patients with
no signs of dysgeusia, none had DM, although 1 expe-
rienced liver cirrhosis. Of the 38 on-chemotherapy
group patients, 14 (36.8%; age: 36–85 years; median
age: 64 years) could not recognize the minimal level
Figure 1 Range of the worst values of taste recognition recorded in each patient. The bars indicate the patients who received
5-fluorouracil (5-FU)-based (red), platinum (Pt)-based (yellow), taxane (Tx)-based (blue), and ifosfamide-based (white) therapies. *indicates
combination therapy with 5-FU.
Figure 2 Reversibility of dysgeusia. The change in dysgeusia in
each patient is plotted both on-chemotherapy and just before the
next therapy cycle (off).
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comorbidities (cerebrovascular disease, epilepsy, brain me-
tastasis, resected laryngeal sarcoma, and DM). Among
the 24 patients who could recognize the minimal level,
4 (16.7%) experienced comorbidities (cerebrovascular
disease, hypothalamic adenoma, meningioma, and DM);
1 patient had both BD and DM. Therefore, patients with
comorbidities appeared to experience dysgeusia at a rate
that was 1.79 times higher than that experienced by
patients with no comorbidity [not significant (NS)]. The
relative risk of dysgeusia between the on- and off-
chemotherapy groups was 1.66 (NS).
Subgroup analysis was performed, although catego-
rizing the on-chemotherapy group patients on the basis
of specific drugs was difficult because of overlapping
combination therapies. Dysgeusia was experienced in
48.1% (13/27) patients who received 5-FU, 25.0% (4/16)
of those receiving Pt, 40.0% (2/5) of those receiving Tx,
and 10.0% (1/10) of those receiving other therapies
(Table 2). Compared with the off-chemotherapy group,
the relative risk of dysgeusia was 2.2 for the oral 5-FU
analog therapy (NS), 1.3 for the intravenous 5-FU the-
rapy (NS), 1.0 for the Pt group, 1.6 for the Tx group
(NS), and 0.4 for patients receiving other therapies. Al-
though the relative risk for oral 5-FU analogs was not
significant, it was higher than the relative risk for the
other therapies. These data suggest that among fre-
quently used chemotherapeutic drugs, oral 5-FU analogs
could be a major risk factor for dysgeusia. Therefore, in
this study, subsequent analyses primarily focused on oral
5-FU-based chemotherapy [17]. Among the 18 patients
who received oral 5-FU analogs, the prevalence of
dysgeusia was as high as 75.0% (6/8) in the patients
aged ≥ 70 years, whereas it was 40.0% (4/10) in thoseaged < 70 years (Table 2). Compared with the patients
aged < 70 years (NS), the relative risk of dysgeusia in the
patients aged ≥ 70 years was 1.8 which implies that oral
5-FU-based therapies cause dysgeusia at a much higher
frequency in patients aged ≥ 70 years than in those
aged < 70 years.
Grades of dysgeusia
Among patients with dysgeusia, the median score was
0.9% (range: 0.8–1.6%). The most severe case was seen
in a patient with local recurrence of laryngeal sarcoma
Imai et al. BMC Palliative Care 2013, 12:38 Page 4 of 5
http://www.biomedcentral.com/1472-684X/12/38who was receiving ifosfamide; he could not recognize a
1.6% salt concentration. Further, 50% patients affected by
dysgeusia could not recognize a 0.8% salt concentration.
The 13 patients with dysgeusia who received 5-FU-based
therapy had a median score of 0.9% (range: 0.8–1.4%;
Figure 1). All 4 of those with dysgeusia who received
Pt-based therapies combined them with 5-FU therapies;
the median for this group was 1.0%, (range: 0.8–1.0%;
Figure 1). The two patients with dysgeusia who received
Tx (one in combination with 5-FU) had scores of 0.8%
(Figure 1). Notably, the severity of dysgeusia tended to
worsen in patients who received 5-FU-based therapy.
Reversibility of chemotherapy-induced dysgeusia
We attempted to assess whether the taste function could
recover after chemotherapy in this study group. However,
we could not document the experience of all patients du-
ring the entire chemotherapy period. Eight patients who
received 5-FU-based therapy agreed to multiple assess-
ments of dysgeusia several times during the course of their
chemotherapy. Among these, recovery of normal taste
function just before the start of the next cycle was con-
firmed in only 3 patients (ages 53, 75, and 77 years;
Figure 2). Recovery of normal taste sensation could not be
confirmed in 5 patients (ages 53, 67, 68, 75 and 78 years;
Figure 2); furthermore, 4 of these 5 patients had a prior
history of chemotherapy, which may have had an impact
on the taste sensations.
Discussion
The prevalence of dysgeusia due to recent chemotherapy
was 38.8% in our hospital. Objective evaluation of the im-
pact of dysgeusia in the clinic requires several types of
procedure, including electrogustometry, whole-mouth
gustatory testing, and magnetoencephalography [18-20].
However, because these procedures are labor-intensive,
they are not suitable for routine evaluation. Among pa-
tients with phantogeusia and parageusia, in one study,
38% reported salty and 22% reported mixed sensations,
such as bitter–salty or sour–sweet [21]. Evaluation of all 5
tastes, including salty, sweet, bitter, sour, and umami is
labor-intensive. Reportedly, except for umami, these tastes
are sensitive to radiotherapy to the same extent [16].
Therefore, alternative approaches are warranted. In this
study, we used the Salsave kit® paper testing because of its
ease of use during routine examinations [22]; it can easily
diagnose dysgeusia, and is adequate for mass screening
and follow-up tests. In addition, this taste strip could
objectively estimate the grade of dysgeusia. Our study
indicated that oral 5-FU analogs may induce dysgeusia
during therapy. These drugs are important therapies for
various types of malignancies, including colorectal, gastric,
mammary, and pulmonary cancers, which are the most
common cancers worldwide. Therefore, in any large-scalestudy of dysgeusia in patients receiving oral 5-FU analogs,
the paper strip test would be convenient for assessing a
larger number of participants.
Interventions to decrease dysgeusia should be developed
to support QOL of patients who receive chemotherapy.
Zinc consumption has been reported to improve taste
sensation affected by radiation [23]. Although glutamine is
known to ameliorate neuropathy induced by cisplatin and
paclitaxel in rats [24], a phase III trial using oral glutamine
failed to prove that it could prevent dysgeusia caused by
taxanes [25]. A standard therapy for dysgeusia caused by
cancer and cancer therapy has not yet been established
[26]. Although the importance of supportive care during
chemotherapy, including use of antiemetics, has been re-
cognized [27,28], future clinical studies in this regard are
warranted. Our study was observational, and we did not
detect any statistically significant differences in the preva-
lence of dysgeusia between the on- and off-chemotherapy
group patients; this could be attributable to the limited
sample size.
Conclusions
We demonstrated that the prevalence of dysgeusia can be
routinely assessed by using an objective, easy-to-use, and
low-cost method involving paper strip testing in patients
who receive chemotherapy. Many patients with cancer ex-
perience dysgeusia caused by chemotherapy. Although
our results should be confirmed by further investigations
in a larger patient population, our findings suggest that
potential dysgeusia in cancer patients should be addressed
to protect their QOL.Abbreviations
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